ProVue Lung blood test detects lung cancers with 89% overall sensitivity and 83% sensitivity at stage I, the earliest and most treatable stage
SAN MATEO, Calif. — May 12, 2026 — PrognomiQ, a healthcare company focused on harnessing the power of proteomics and multi-omics data to transform the detection and early treatment selection and monitoring of cancer, today announced encouraging early results from the first patients tested with ProVue Lung. This novel blood-based Laboratory Developed Test (LDT) is designed to support the early detection of lung cancer in high-risk individuals.
Read the full article here.
